1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Episurf Medical AB (publ)
  6. News
  7. Summary
    EPIS B   SE0003491562

EPISURF MEDICAL AB (PUBL)

(EPIS B)
  Report
Delayed Nasdaq Stockholm  -  05/17 11:29:41 am EDT
2.310 SEK   +0.22%
05/02Episurf Medical - Q1'22 Review
AQ
04/29Change in number of shares and votes in Episurf Medical
AQ
04/29Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Episurf Medical hires Stephen Caswell to head Global Sales OUS

12/03/2021 | 02:01am EDT

Episurf Medical (NASDAQ: EPIS B) today announces the hiring of Stephen Caswell as Head of Sales, OUS. In this role Stephen will define and execute upon the strategic sales strategy for Episurf's markets outside of the U.S and Canada, working closely with the company's direct sales force and indirect sales partners to accelerate growth. Ensuring that more patients in this under-served segment can benefit from a personalized treatment platform to help reduce pain and maximise function. Stephen will provide an acute focus on driving business acceleration, market development and brand positioning within the international markets.

Stephen has spent the last 7 years with Stryker's Joint Replacement division in various roles covering direct sales, sales management and marketing of Mako Robotics with a focus on both public and private sectors, and most recently held the position of Commercial Director of Strategic Capabilities. In his Mako Robotics role, Stephen focused on marketing of patient specific 3D planning tools for knee replacement procedures.

Prior to Stryker, Stephen practiced as a registered Physiotherapist for 11 years, working in both the U.K public and private sectors. In this segment, he built a company that was later sold. Stephen also has a BSc First Class Hons degree in Physiotherapy, MSc Sports Medicine and an Executive MBA.

"I am incredibly passionate about this under-served patient segment" explains Stephen; "With the combination of detailed 3D planning and damage reporting, patient specific implants and 3D printed patient specific instrumentation, we have a fantastic opportunity to expand the use of this treatment platform to provide improved outcomes for this high functioning patient group". Stephen goes on to explain "when this is combined with the robust clinical data the company have diligently captured, we are well placed to see significant growth across multiple markets".

"I am pleased with having Stephen onboard for this incredibly important assignment. In addition to his strong industry experience, Stephen is highly passionate about helping patients, evidenced by his background in physiotherapy. Episurf is moving from research and development into the commercial phase, and Stephen will play an important role in ensuring that we are taking the next steps", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 3 December 2021.

https://news.cision.com/episurf/r/episurf-medical-hires-stephen-caswell-to-head-global-sales-ous,c3465447

https://mb.cision.com/Main/14691/3465447/1505186.pdf

https://news.cision.com/episurf/i/stephen-caswell,c2988022

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about EPISURF MEDICAL AB (PUBL)
05/02Episurf Medical - Q1'22 Review
AQ
04/29Change in number of shares and votes in Episurf Medical
AQ
04/29Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/26Episurf Medical's First Ankle Implant Surgery Scheduled In Belgium
MT
04/26First Episealer« Talus surgery planned in Belgium
AQ
04/25Episealer« presentation at the 20th ESSKA Congress, held on April 27-29 in Paris, Franc..
AQ
04/24Episurf Medical's Episealer« Patellofemoral System under substantive review at the US F..
AQ
04/24Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral Syst..
CI
04/20New patent approval in Hong Kong for Episurf Medical
AQ
04/19Episurf Medical To Win New European Patent For Joint Implant
MT
More news
Financials
Sales 2022 10,7 M 1,08 M 1,08 M
Net income 2022 -72,0 M -7,26 M -7,26 M
Net cash 2022 165 M 16,6 M 16,6 M
P/E ratio 2022 -8,12x
Yield 2022 -
Capitalization 616 M 62,0 M 62,0 M
EV / Sales 2022 42,2x
EV / Sales 2023 25,2x
Nbr of Employees 31
Free-Float 79,4%
Chart EPISURF MEDICAL AB (PUBL)
Duration : Period :
Episurf Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPISURF MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,31 SEK
Average target price 5,65 SEK
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Pňl Ryfors Chief Executive Officer & Sales Director
Veronica Wallin Chief Financial Officer
Dennis D. Stripe Chairman
Katarina Flodstrom Chief Operating Officer
Carl Christian KrŘeger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EPISURF MEDICAL AB (PUBL)-49.34%61
STRYKER CORPORATION-12.55%88 431
SMITH & NEPHEW PLC0.04%13 800
INSPIRE MEDICAL SYSTEMS, INC.-28.85%4 516
AXONICS, INC.-15.48%2 228
DOUBLE MEDICAL TECHNOLOGY INC.-36.11%2 027